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Abstract: The goal of present work was to investigate the use of bioerodible polymeric 
nanoparticles as carriers of retinoic acid (RA), which is known to induce differentiation of 
several cell lines into neurons. A novel method, named “Colloidal-Coating”, has been 
developed for the preparation of nanoparticles based on a copolymer of maleic anhydride 
and butyl vinyl ether (VAM41) loaded with RA. Nanoparticles with an average diameter 
size of 70 nm and good morphology were prepared. The activity of the encapsulated RA 
was evaluated on SK-N-SH human neuroblastoma cells, which are known to undergo 
inhibition of proliferation and neuronal differentiation upon treatment with RA. The 
activity of RA was not affected by the encapsulation and purification processes.  
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1. Introduction 
 
Recently, Tissue Engineering (TE) has become a well recognized technique, and many researchers 
with different areas of expertise are entering this medical field, thereby increasing its scientific 
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implications. The objective of tissue engineering is to regenerate natural tissues from living cells to 
replace defective or lost tissues and organs [1]. 
It is undoubtedly necessary for cell-based tissue regeneration to increase the number of cells that 
constitute the tissue, as well as reconstruct the structure to support the cells. In addition, growth factors 
are required to promote cell differentiation and proliferation and thus achieve tissue regeneration. 
However, few researchers have applied this Drug Delivery System (DDS) to the field of Regenerative 
Medicine (RM) [2]. Drugs for RM include organic compounds and genes that are effective in 
promoting the proliferation and differentiation of cells for the induction of tissue and organ 
regeneration [2]. 
RA, the main biologically-active derivative of Vitamin A or retinol [3], is a potent regulator of gene 
transcriptions [4], and play an important role in regulating cell growth, differentiation [3], embryonic 
development, apoptosis, homeostasis [5] and can reverse malignant cell growth in vitro and in vivo. 
All-trans-retinoic acid (ATRA) is being increasingly included in antitumour therapeutical schemes for 
the treatment of various tumoral diseases such as acute promyelocytic leukaemia, Kaposi’s sarcoma, 
head and neck squamous cell carcinoma, ovarian carcinoma, bladder cancer and neuroblastoma [6] and 
has shown antiangiogenic effects in several systems [5]. As a result of good clinical responses in 
treatment of these malignancies, retinoids are being investigated for their therapeutic potential in an 
increasing range of diseases [3]. However, due to its hydrophobicity [6] (0.21 µM in physiological 
solution, pH 7.3) [7], and short half-life in blood [8], ATRA parenteral administration is very difficult 
and to date no commercial parenteral formulation is available. On the other hand the oral formulations 
in clinical use are characterized by uncertain drug bioavailability due to the variable absorption in the 
gastrointestinal tract and the hepatic first pass effect, implying metabolism by hepatocytes of ATRA to 
less active compounds. Furthermore its intestinal absorption is affected by the pH and fatty acid 
composition of intraluminal bile [9]. Therefore, plasma concentration following oral administration of 
ATRA is highly variable [6]. In addition to the poor solubility, combined with chemical instability of 
ATRA complicates its administration.  
In spite of its pronounced therapeutical effect, several side effects such as teratogenicety [10], 
retinoid acute resistance, hypertriglyceridemia, mucocutaneous dryness, headache [11] hepatotoxicity, 
nausea, vomiting, and abdominal pain [3] are reported and limit the clinical applications of ATRA [8]. 
Different treatment modalities have been investigated in attempt to overcome the accelerated 
metabolism of ATRA that leads to a progressive decline in plasma ATRA concentrations during a 
chronic daily schedule. These modalities include the use of inhibitors of cytochrome p450 enzymes, 
administration of oral ATRA on an intermittent schedule, and encapsulation of ATRA into 
microspheres [12], microemulsions [13], nanodisks [14], liposomes [15], micelles [16] and 
nanoparticles [6,8,9,17,18]. The dimensions of the carrier have a critical role in the achievement of 
optimized therapeutic regimens. It has been shown that nanocarriers can penetrate through small 
capillaries, across numerous physiological barriers and can be taken up by cells, thus inducing efficient 
drug accomulation at the target site [20]. 
There are a number of techniques available for the preparation of drug loaded nanoparticulate 
systems such as the emulsion solvent evaporation/extraction method, spray drying, phase separation-
coacervation, interfacial deposition, and in situ polymerization. Each method has its own advantages Int. J. Mol. Sci. 2009, 10                 
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and disadvantages. The choice of a particular technique depends on polymer and drug features, site of 
action and therapy regimes [21]. 
Although a number of different method exist for the preparation of nanoparticles the choice of a 
preparation method is an hard task and general procedures that works for all nanoparticles material 
seem to do not exist. Furthermore it is highly desirable to provide with alternative methods, aimed at 
producing polymeric particles, that do not entail the utilization of organic solvents that are 
undesiderable for their potential toxicity. Such a method is expected to receive a particular attention in 
biotechnological field [21].  
In this work an organic solvent-free method has been developed for the preparation of VAM 41 
nanoparticles loaded with RA. VAM 41 is an amphiphilic polymeric material developed by 
hemiesterification of alternating copolymers of maleic anhydride (MAn) and alkyl vinyl ethers (RVE) 
Quite a large number of examples are reported in the literature in which hemiesters of copolymers of 
maleic anhydride and alkyl vinyl ethers have been utilized for the formulation of release systems. For 
instance, the n–butyl hemiester of maleic anhydride–methyl vinyl ether alternating copolymer has been 
used in ophthalmology for the preparation of monolithic systems or as pH sensitive covers of 
microcapsules [22]. Similarly, alkyl hemiesters of maleic anhydride–oligo(oxyethylene) vinyl ether 
copolymers were formulated as monolithic inserts for the controlled release of pilocarpine [23], and γ-
interferon [22,24]. 
The developed method is easy to be perform, effective for the preparation of relatively small 
nanoparticles with a narrow size distribution and is operator friendly, since it does not require handling 
any toxic organic solvents. The SK-N-SH neuroblastoma cell line was chosen as a model to verify the 
possibility of differentiating for a neuronal phenotype after exposure to bioactive principles and to 
examine whether the activity of RA was affected by incorporation in VAM41 nanoparticles by the 
developed method. The preparation process guarantee for the chemical stability and biological activity 
of the incorporated drug. 
 
2. Results and Discussion 
 
The novel nanoparticle preparation method was conceived by taking into account the characteristics 
of RA, VAM41 and HSA and the behaviour of their different mixtures in response to pH variations. 
RA is a hydrophobic compound with one polar, ionisable end group that confers amphiphilic character 
to the molecule. In non-polar hydrocarbon solvents, RA self associates by forming tail-to-tail dimers 
that are stabilized by hydrogen bonding between the carboxyl groups of two RA molecules. On the 
contrary, in water RA self associates in micelle-like structures by hydrophobic interaction among the 
rings of several molecules [25]. RA at pH > 7.4 and at a 1.5 mM concentration is soluble in water, as 
evidenced by the clarity of the solution and the lack of any observed light scattering. When the pH is 
lowered to 7, RA self associates to micellar like structure with a diameter of 120 nm. This 
phenomenon is macroscopically evidenced by the appearence of turbidity and the size evaluated by 
granulometry measurements. A further decrease of the solution pH causes the formation of flakes of 
micelles that leads to RA precipitation. At a pHs below the critical micellar concentration which is 
about 2 x 10
-6 mol/L (pH 7) [26], the negative surface charge which stabilize the RA micelles is 
gradually lost. Particles collide forming aggregates that precipitate. Int. J. Mol. Sci. 2009, 10                 
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In presence of HSA (nHSA/nRA 1:10) a stable yellowish milky-like particle suspension with a 
diameter size of 90 nm forms at pH 7. HSA hampers the precipitation of the drug up to pH 5. 
However, at pHs below 5 the colloidal suspension looses its stability and tends to agglomerate.  
This behaviour could be explained by the so-called hydration forces [27]. HSA, once its binding 
sites for RA are saturated, tends to be adsorbed on the RA colloid’s surface. It is well established that 
water molecules strongly bind to protein surfaces. An overlap of the solvent layers near to the two 
mutually approaching colloid surfaces creates repulsive forces [28]. At pH 5, a pH lower than the 
isoelectric point (pI) of HSA, protein molecules have a compact coil structure and an electrostatic 
attraction force favours the protein (positively charged) surface union [27] which leads to the loss of 
colloidal stability of the system. VAM41, due to the presence of the ionisable carboxylate group is 
soluble in water at pHs above 8 and it is insoluble at pHs below 7 (Figure 1). HSA, as previously 
reported, is able to complex RA and stabilize suspension colloidal particles, is soluble at all mentioned 
pHs, and due to the presence of many charged residues on the molecule, it has buffering properties. At 
physiological pH (7.4) it displays a net negative charge [29]. 
Figure 1. Carboxylic acid moieties confer amphiphilic behaviour to RA (A) and water 
solubility to VAM41 (B). 
A B 
 
 
It was observed that the addition of a drop of 1N chloride acid to a water solution of VAM41 and 
HSA at pH 8 led, as expected, to the formation of polymer flakes. Unexpectedly, after few seconds 
under energetic stirring, these flakes completely re-dissolved. HSA, thanks to its buffering properties, 
was able to deprotonate the carboxylic moieties of VAM41. The further addition of drops of acid led to 
a slow decrease of the pH of the solution, to a reduction of the ability of HSA to accept protons and a 
milk-like colloidal suspension of VAM41 formed at about pH 6. At pH 5.5 a colloidal suspension of 
VAM41 with average diameter size of the particles of 2.74 µm (polydispersity: 0.3) and a rather wide 
distribution of the diameters (Figure 2) was observed that became 4.64 µm at pH 2.5. 
On the basis of this observation and keeping in mind the characteristics of the material employed, a 
water solution of VAM41, RA and HSA was prepared by adding NaOH to a water suspension of the 
materials. The solution pH was adjusted to 8 and subsequently drops of HCl 1 N and 0.1 N, as in a 
typical titration experiment, were added under energetic stirring in order to prepare nanoparticles. As 
already experienced, the addition of drops of acid to the solution led to the formation of flakes that 
rapidly re-dissolved. As hypothesized, at roughly pH 7.4 micelles of RA formed, while the polymer 
kept re-dissolving in the same fashion. The subsequent additions of acid caused the polymer to absorb 
and coat uniformly the surface of the formed colloidal suspension. The energetic stirring was essential 
O
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for a uniform distribution of the polymer onto RA micelles. HCl 1 N was used in the first part of the 
experiment when the dissolution of the forming flakes was quite fast. Once the buffering properties of 
HSA were reduced, HCl 0.1 N was used to terminate the covering process. RA acted as nucleating 
agent during the preparation of nanoparticle suspensions.  
Figure 2. Particle size distribution obtained from a water solution containing VAM41   
and HSA.  
 
 
The colloidal suspension was stable up to pH 5.3. Below this pH particles joined together forming a 
dense aggregate that could be uniformly redispersed just by adding drops of dilute NaOH. The 
formation of aggregates could be ascribed to the above mentioned loss of proteins stabilizing effect at 
pHs close or below to their pI. Particle formation and development was followed by pHmeter and light 
scattering (Table 1).  
Table 1. Correlation between pH, size and macroscopic appearance of nanoparticles 
suspensions prepared by Colloidal-Coating. 
pH 
Diameter (nm) 
number % ± SD 
Polydispersity 
Index 
Macroscopic observations 
8 -  -  yellowish solution 
7.5  59 ± 11  0.1  slight yellowish milky like 
suspension 
6.2  n.d.  n.d.  dense yellowish milky like 
suspension 
5.2  87 ± 44  0.2  presence of agglomerates in solution 
5.7  78 ± 17  0.1  yellowish milky like suspension 
5.3  69 ± 14  0.1  dense yellowish milky like 
suspension 
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Nanoparticles with good morphology and an average diameter size of about 65 nm were prepared 
using this technique (Figure 3). 
 
Figure 3. Morphology (A) and particle size distribution (B) of RA loaded nanoparticles 
prepared by Colloidal Coating (pH 5.3). 
A B 
 
Moreover a drug loading content of 6.7% with a loading efficiency of 97% was obtained when the 
experiment was terminated at pH 5.3. Drug loading efficiency is very high and depends on the extent 
of acidification of the solution, since the lower is the pH reached, the higher is the amount of polymer 
that covers and forms nanoparticles. This formulation method is basically suitable for any material 
with water solubility influenced by the pH.  
During the preparation of nanoparticles by Colloidal Coating, RA is subjected to pH variations, 
freezing and drying process. In order to examine whether the activity of RA was affected by 
incorporation in VAM41 nanoparticles, it was tested on SK-N-SH human neuroblastoma cell line that 
are known to undergo inhibition of proliferation and neuronal differentiation upon treatment with RA. 
SK-N-SH neuroblastoma cell line was chosen as a model to verify the possibility to differentiate 
towards a neuronal phenotype after exposure to bioactive principles.  
Numerous studies have shown that RA induces differentiation, growth arrest, and apoptosis in 
neuroblastoma cell lines by inhibition of telomerase activity, and in increased endogenous ceramide 
levels [30]. Results of the qualitative investigations of SK-N-SH cells treated with RA loaded 
nanoparticles appear to indicate a growth inhibition in respect to the untreated cells (negative control) 
(Figure 4), thus suggesting that the antiproliferative and differentiating activity of RA was not 
impaired by the nanoparticles incorporation and freeze-drying process. Observation of cells treated 
with free RA indicates a higher growth inhibition activity in respect to the RA loaded into 
nanoparticles. It is reasonable to speculate that this result is related to a controlled release of the 
bioactive agent RA from nanoparticles.  
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Figure 4. Bright Field Microscopy evalution of SK-N-SH morphology in samples 
untreated (negative control), treated with free RA (RA positive control) and with 
nanoparticles loaded with RA (VAM41 Nps). 
Control    RA    VAM41  Nps 
     
D a y   1      D a y   1      D a y   1  
     
D a y   2      D a y   2      D a y   2  
     
D a y   3      D a y   3      D a y   3  
     
D a y   6      D a y   6      D a y   6  
 
3. Experimental Section 
 
3.1. Materials 
 
The bioerodible polymer VAM41 [2-methoxyethanol hemiester of poly(maleic anhydride-alt-butyl 
vinyl ether)] was kindly provided by Polymer Laboratories Ltd (UK). Retinoic acid (RA) and human 
serum albumin (HSA, 96 – 99% powder) were purchased from Sigma (St. Louis, MO, USA). A 3% 
mannitol solution was prepared by dissolving 3.0 g of mannitol (Baker) in 100 mL distilled water 
(Phillipsburg, NJ, USA). Hydrochloric Acid 37 – 38% the commercial product (J.T. Baker, Int. J. Mol. Sci. 2009, 10                 
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Philipsburg, NJ, USA) was used as received and diluted with deionised water to prepare 1 N and 0.1 N 
acid solutions. SK-N-SH human neuroblastoma cell line (HTB-11) was purchased from American 
Type Culture Collection (ATCC, Rockville, MD) and propagated as indicated by the supplier. 
Minimum Essential Medium (MEM), 0.01 M phosphate buffer saline (pH 7.4) free of Ca
2+ and Mg
2+ 
(PBS), fetal calf serum, glutamine and antibiotics (penicillin/streptomycin) were purchase from 
GIBCO Brl (Rockville, MD). 
 
3.2. Preparation of Unloaded Nanoparticles 
 
50 mg of VAM41 were dissolved in 5 mL of water by adding a drop 10 N NaOH and then 200 µL 
of 25 % HSA solution (corresponding to 50 mg HSA) were added. The solution was left under stirring 
conditions for 1 h and the pH was adjusted to 8. At room temperature and under rapid magnetic 
stirring (7,500 rpm) 1 N HCl was dropped into the solution until the formation of a suspension   
(~ pH 5). Each drop was added after the disappearing of the flakes formed by the addition of the  
previous drop. 
 
3.3. Preparation of RA Loaded Nanoparticles 
 
50 mg of VAM41 were dissolved in 5 mL of water by adding a drop 10 N NaOH and then 200 µL 
of 25 % HSA solution (corresponding to 50 mg HSA) were added and the solution was kept under 
stirring condition for 1 h. Subsequently 225 µL of a solution of retinoic acid in DMSO (10 mg/mL) 
were added and the pH was adjusted to 8. At room temperature and under rapid magnetic stirring 1 N 
HCl was dropped into the solution until the formation of a yellowish suspension (~ pH 7.4). Each drop 
was added after the disappearing of the flakes formed by the addition the previous drop. In the same 
fashion drops of 1 N and 0.1 N HCl were added up to pH 5.3. 
 
3.4. Nanoparticles Purification 
 
Nanoparticle suspensions were purified by centrifugation in an ALCPK121R centrifuge at 8,000 g 
for 30 minutes at room temperature in order to remove the excess of polymer, drug and protein. The 
samples were either placed in 50 mL falcon or in Eppendorf tubes and centrifuged by using AM-10 or 
AM-21 rotors, respectively. Harvested nanoparticles were freeze-dried in a 5Pascal Lio 5P 
lyophilizator.  
 
3.5. Cryoprotection 
 
Nanoparticle suspensions (6.0 mL) were centrifuged at 8,000 g for 30 minutes. The resulting pellets 
were dispersed in 3.0 mL of aqueous solutions containing 3 % mannitol. The resulting suspensions 
were frozen at -20 °C, freeze-dried in a 5Pascal Lio 5P lyophilizator. The recovered lyophilized 
powders were re-dispersed in 3.0 mL of deionised water. 
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3.6. Nanoparticle Characterization 
 
Size Analysis: dimensional analyses were carried out by using a Coulter LS230 Laser Diffraction 
Particle Size Analyzer, equipped with small volume module plus. Nanoparticle suspensions were 
added into the cell until 30 – 50% obscuration of PIDS detector was reached. Deionised water was 
used as background and diameter distribution was processed using the Fraunhofer optical model. Three 
runs were performed on each sample.  
Morphological Analysis: nanoparticles morphology was investigated by means of scanning electron 
microscopy (SEM), by using a JEOL LSM5600LV scanning electron microscope. Gold sputtering was 
performed before SEM analysis. 
 
3.7. Evaluation of Retinoic Acid Incorporation 
  
Samples of purified and lyophilised VAM41 nanoparticles were weighted properly and dissolved 
into 5 mL of water by adding 1 N NaOH. The final pH was adjusted to 8. Drug concentration was 
determined spectrophotometrically
 [31] at 347 nm by using a standard curve obtained by plotting the 
average blank-corrected absorbance of each standard vs. its RA concentration (0.04 – 10 mg/L;   
y = 0.1823x + 0.0.0051; R
2 = 0.9994). 
 
3.8. In Vitro Evaluation of Encapsulated Retinoic Acid Activity  
 
SK-N-SH human neuroblastoma cells were seeded in 6 multi-well plates (1.5 × 10
4 cells/well) and 
maintained in Minimum Essential Medium (MEM) containing 10% fetal calf serum, 4 mM glutamine 
and 100 U/mL:100 µg/mL penicillin:streptomycin at 37 °C in 5% CO2 for 24 h. Cells were treated 
either with 40 µM free-RA or 40 µM encapsulated RA for 6 days. Encapsulated or free RA was added 
to the cells in fresh growth media at every 48 h and morphological differentiation assessed by phase 
contrast microscopy, by using a Nikon TE-2000 inverted microscope. 
 
4. Conclusions 
 
An organic solvent-free method, called “Colloidal-Coating”, has been developed for the preparation 
of VAM 41 nanoparticles loaded with RA. This method presents numerous advantages when 
compared with the other nanoparticles preparation methods. It does not entail the utilization of toxic 
organic solvents with obvious implications from a biocompatibility point of view, it is easy to perform, 
allows for the formulation of small nanoparticles with narrow size distribution, it is based on a 
reversible process and wastes of material in case of accidental errors during the preparation are 
avoided. It is possible to prepare multi-layer nanocapsules by adding at different stages of the 
preparation functionalized polymers and might be extended for the preparation of ferrofluids or in 
general to encapsulate any substance that can act as nucleating agent. The activity of RA encapsulated 
by colloidal-coating method was evaluated. The data obtained suggested that the antiproliferative and 
differentiating activity of RA was not impaired by incorporation and purification processes. SK-N-SH Int. J. Mol. Sci. 2009, 10                 
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neuroblastoma cell line was chosen as a model to verify the possibility to differentiate towards a 
neuronal phenotype after exposure to bioactive principles. 
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